»ùÒò¹¤³ÌÂÛÎÄ

Äúµ±Ç°µÄλÖãºÑ§ÊõÌà > ÉúÎïѧÂÛÎÄ > »ùÒò¹¤³ÌÂÛÎÄ >

Ñо¿ºÍÓ¦ÓÃÖí¸ÉÈÅËئÁµÄ»ùÒò¹¤³ÌÒâÒå̽ÌÖ

À´Ô´£ºÉϺ£ÐóÄÁÊÞҽͨѶ ×÷Õߣº¹ù¼Ñºê;ÏÄÒ¶;
·¢²¼ÓÚ£º2018-12-19 ¹²12579×Ö

¡¡¡¡ÎÒ¹úÊÇÑøÖí´ó¹ú, ÑøÖíÒµÔÚ¹úÃñ¾­¼ÃÖоÓÓÚÊ®·ÖÖØÒªµÄµØλ¡£µ«ÖíÔ²»·²¡¶¾²¡¡¢ÖíÎÁ¡¢¿ÚÌãÒß¡¢Öí·±Ö³ÓëºôÎü×ÛºÏÕ÷¡¢Öíα¿ñÈ®²¡¡¢ÖíÁ÷ÐÐÐÔ¸¹Ðº¡¢Öí´«È¾ÐÔ賦Ñ׵Ȳ¡¶¾ÐÔÒß²¡ÒѳÉΪµ±Ç°À§ÈÅÑøÖíÒµ·¢Õ¹µÄÖØ´óÎÊÌâ, ÿÄêÒò²¡¶¾¸ÐȾ¶øÔì³ÉµÄËðʧÎÞ·¨¹ÀÁ¿¡£¶ÔÕâЩ³£¼ûµÄ²¡¶¾²¡, ËäÈ»ÓÐЩ¿ÉÓÃÒßÃç×÷³£¹æÃâÒß, µ«ÓÉÓÚÃâÒß³ÌÐò¡¢ÒßÃç±¾ÉíºÍ¶¯Îï¸öÌåµÈÔ­Òò, ʹÆäÔÚʵ¼ÊÓ¦ÓÃÖеÄЧ¹û²¢²»Ê®·ÖÀíÏë¡£¸ÉÈÅËØ (interferon, INF) ÊÇÓÉϸ°û²úÉúµÄÒ»Àà¾ßÓй㷺µÄ¿¹²¡¶¾¡¢¿¹Ö×ÁöºÍÃâÒßµ÷½Ú»îÐԵĵ°°×ÖÊ, ÊÇÄ¿Ç°Ó¦ÓÃÇ°¾°½ÏΪ¹ãÀ«µÄÉúÎïÖƼÁÖ®Ò»¡£Öí¸ÉÈÅËØ¿É·ÖΪ!¡¢"¡¢#¡¢$¡¢%µÈ¼¸¸öÐÍ, ÆäÖÐ!¡¢"¡¢$¡¢%µÈÊôIÐ͸ÉÈÅËØ, #ÊôIIÐ͸ÉÈÅËØ¡£Ñо¿±íÃ÷, Öí¸ÉÈÅËØ!¶Ôα¿ñÈ®²¡¶¾[1]¡¢´«È¾ÐÔ賦Ñײ¡¶¾[2,3]¡¢ÖíÎÁ²¡¶¾[4]¡¢ÖíºôÎüÓë·±Ö³×ÛºÏÖ¢²¡¶¾[5,6,7,8,9,10,11,12]ºÍ¿ÚÌãÒß²¡¶¾[13,14,15,16]µÈ¾ù¾ßÓнϺõĿ¹²¡¶¾×÷Óá£ÁíÍâ, ½üÄêÀ´µÄÑо¿·¢ÏÖ, Öí¸ÉÈÅËØ!¶Ô¿ÚÌãÒß²¡¶¾±íλÒßÃç[17,18]¡¢¿ÚÌãÒß²¡¶¾VP1Ñǵ¥Î»ÒßÃç[19]µÈ»ùÒò¹¤³ÌÒßÃç¾ù¾ßÓÐÃâÒß×ô¼Á×÷ÓÃ, ²¢¶ÔÖí¿ÚÌãÒß[13,14,15,20]ºÍÖí´«È¾ÐÔ賦Ñ׵ȶàÖÖ²¡¶¾ÐÔ´«È¾²¡¶¼ÓÐÒ»¶¨µÄ·ÀÖÎЧ¹û¡£¹ú¼Ò¸÷²¿Î¯¶ÔÖí¸ÉÈÅËØ!µÄÑо¿Ò²´Ó²»Í¬µÄ;¾¶¸øÓèÁËÖ§³Ö, Èç“Ê®Î唹ú¼ÒÖØ´óרÏî¿Æ¼¼¹¥¹Ø¼Æ»®¿ÎÌâ (2002BA514A2-2) ¡¢¹ú¼Ò“ʮһÎ唿Ƽ¼Ö§³Å¼Æ»®×¨Ïî (2006BAD06A08) ¡¢¹ú¼ÒÖصã»ù´¡Ñо¿·¢Õ¹¼Æ»® (973) ÏîÄ¿ (2006CB504401) ¡¢¹ú¼Ò“863”¼Æ»®×ÊÖúÏîÄ¿ (2002AA245071) ºÍ¹ú¼ÒÐÐҵרÏî×Ó¿ÎÌâ (200803020-4) µÈ¡£

»ùÒò¹¤³Ì

¡¡¡¡1 Öí¸ÉÈÅËØ!µÄ·Ö×ӽṹ

¡¡¡¡Öí¸ÉÈÅËØ!Ö÷ÒªÓÉÁÜ°Íϸ°û²úÉú, Óжà¸öÑÇÐÍ, Æ俹²¡¶¾×÷ÓÃ×î¹ã¡¢Ð§¹û×îÏÔÖø¡£1986ÄêLEFE-VREµÈ[21]Ê×ÏÈ´ÓÖíµÄ»ùÒò×éÎÄ¿âÖпË¡³öÁË10¸öDZÔÚµÄÖí¸ÉÈÅËØ!»ùÒò, ²¢Ôڴ󳦸˾úÖбí´ï³öÖí¸ÉÈÅËØ!1, ²»¹ý±í´ïÁ¿½ÏµÍ¡£Öí¸ÉÈÅËØ!»ùÒòÎÞÄÚº¬×Ó, ±àÂë189¸ö°±»ùËá, Ç°23¸ö°±»ùËáΪÐźÅëÄ, ºó166¸ö°±»ùËáΪ³ÉÊì»îÐÔµ°°×¡£³ÉÊìÖí¸ÉÈÅËØ!µÄ70~80λ°±»ùËáÓÐ1¸öDZÔÚµÄN-ÌÇ»ù»¯Î»µã, ÔÚ1~99λ¡¢29~139λ֮¼äÐγÉ2¸ö¶þÁò¼ü, ÆäÖÐ29~139λ֮¼äµÄ¶þÁò¼ü¶ÔÓÚIFNµÄÉúÎïѧ»îÐÔ¸üΪÖØÒª¡£ÓëHuIFN-!lºËÜÕËáÐòÁеÄͬԴÐÔΪ78.5%, °±»ùËáͬԴÐÔΪ64%¡£YERLEµÈ[22]·¢ÏÖÖí¸ÉÈÅËØ!»ùÒòλÓÚ1ºÅȾɫÌåÉÏ¡£CHENGµÈ[23]´ÓÖíµÄ»ùÒò×éÖмø±ð³öÁË14¸öÖí¸ÉÈÅËØ!»ùÒò¡£

¡¡¡¡2 Öí¸ÉÈÅËØ!»ùÒò¹¤³Ì

¡¡¡¡ÁÙ´²ÉÏ, Öí¸ÉÈÅËØ!¶Ô²¡¶¾ÐÔ¼²²¡¾ßÓнϺõķÀÖÎЧ¹û¡£ÏÖÔÚËäÒÑÓÐÉÌÆ·»¯µÄÊÞÓøÉÈÅËØÉÏÊÐ, µ«ÕâЩ¸ÉÈÅËØÖ÷ÒªÊÇÓÉÌض¨µÄÓÕµ¼¼ÁÓÕµ¼²úÉúµÄ, ÖƱ¸¹¤ÒÕ¸´ÔÓ, ²úÁ¿µÍ, ³É±¾¸ß¡£WEINGARTLµÈ[24]ÓÅ»¯ÁËÓ¦ÓÃNDVÓÕµ¼ÖíÍâÖÜѪÁÜ°Íϸ°ûÉú²úÖí°×ϸ°û¸ÉÈÅËصÄÌõ¼þ, ·¢ÏÖµ±ÍâÖÜѪÁÜ°Íϸ°ûµÄŨ¶ÈΪ9.6×106¸ö/mL, ÏÈÓÃ64U/mLÖí¸ÉÈÅËØ!·õÓý18hºóÔÙÓÃ4 915HAU/mL NDVÓÕµ¼24h, ×î¸ß¿É»ñµÃ12 800U/mLÖí°×ϸ°û¸ÉÈÅËØ¡£1990ÄêLEFEVREµÈ[25]¹¹½¨ÁËpLD67MetIFN-!1&HS/CAGl139±í´ïϵͳ, Ôڴ󳦸˾úÖбí´ï³öÖØ×éµÄ³ÉÊìÖí¸ÉÈÅËØ!1 (rIFN-!1) , ÔÚMDBKϸ°ûÉÏ¿¹VSV²¡¶¾»îÐÔ´ï5×107~10×107 IU/mg, rIFN-!1µÄ¿¹²¡¶¾»îÐÔÊDz¡¶¾ÓÕµ¼µÄ°×ϸ°û¸ÉÈÅËصÄ6±¶¡£Òò´Ë, ÀûÓûùÒò¹¤³Ì¼¼ÊõÉú²úÖØ×éÖí¸ÉÈÅËØ!ÊÇ¿ÉÐеÄ, ¶Ô»ù´¡Ñо¿ºÍÓ¦ÓÃÑо¿¾ù¾ßÓÐÖØÒªµÄÒâÒå¡£

¡¡¡¡½üÄêÀ´, ¹úÄÚÓ¦ÓûùÒò¹¤³Ì¼¼Êõ±í´ïÖí¸ÉÈÅËØ!µÄ±¨µÀÖð½¥Ôö¶à¡£

¡¡¡¡2.1 Öí¸ÉÈÅËØ!Ôڴ󳦸˾ú±í´ïϵͳÖеıí´ï

¡¡¡¡21ÊÀ¼ÍÒÔÀ´, ¹úÄÚÐí¶àѧÕß½øÐÐÁËÀûÓô󳦸˾ú±í´ïϵͳ±í´ïÖí!¸ÉÈÅËصÄÑо¿, »ñµÃµÄÄ¿±êµ°°×ÖÊҪô±í´ïÁ¿µÍ, ҪôÒÔ°üº­ÌåÐÎʽ±í´ï, ÐèÒª¾­±äÐÔ¡¢¸´ÐԵȷ±ÔӵIJÙ×÷, ÄÑÒÔÊÊÓ¦¹æÄ£»¯Éú²úºÍÓ¦ÓõÄÐèÒª¡£Èç³ÂÌεÈ[26]¹¹½¨ÁËpGEX-IFN/BL21±í´ïϵͳ, ½«ÒÔ°üº­ÌåÐÎʽ±í´ïµÄÄ¿µÄµ°°×¾­±äÐÔ¡¢¸´ÐÔ´¦Àí, ÔÙ¾­FPLC½øÒ»²½´¿»¯, µÃµ½µÄÖØ×éÖí¸ÉÈÅËØ!µÄ»îÐÔΪ5 200IU/mg¡£ÎⵤµÈ[4,27]¹¹½¨ÁËpQE30/PoIFN!/JM109±í´ïϵͳ, ±í´ïµÄrPoIFN-!N¶Ëº¬6¸ö×é°±Ëá±êÇ©, Ïà¶Ô·Ö×ÓÖÊÁ¿2.07×104, ÒÔ°üº­ÌåÐÎʽ´æÔÚ, ¾­²¿·Ö´¿»¯²¢³ä·Ö¸´ÐÔºó, ÔÚMDBKϸ°ûÉÏ¿¹ÂËÅÝÐÔ¿ÚÑײ¡¶¾ (VSV) µÄ»îÐԸߴï1×108 IU/mL, 103ºÍ105 IUµÄrPoIFN-!ÔÚPK-15ϸ°ûÉÏÓÐЧÒÖÖÆÖíÎÁ²¡¶¾ (HCV) ʯÃÅϵ (SM) Ç¿¶¾µÄ¸ÐȾ¡£²ÜÈð±øµÈ[28]¹¹½¨ÁËpCIFNA/DH5!±í´ïϵͳ, ±í´ï²úÎïÒÔ°üº­ÌåÐÎʽ´æÔÚ, Óú¬6mol/LÑÎËáëҵıäÐÔÒºÈܽ⼰º¬GSH-GSSG¸´ÐÔÒº¸´ÐÔ´¦Àí, ¸´ÐÔºóµÄ±í´ï²úÎï¾­Äý½º²ãÎö´¿»¯, ÔÚMDBK/VSVϵͳÉϵĿ¹²¡¶¾»îÐÔԼΪ1.66×106 U/mg¡£²ÜÈð±øµÈ[29]ΪÁË»ñµÃpoIFN-!1¸ß±í´ï, ʹÓÃÁ˴󳦸˾úµÄÆ«°®ÃÜÂë×Ó, È˹¤ºÏ³ÉÁËpoIFN-!1³ÉÊìµ°°×±àÂë»ùÒò¡£ÀûÓúϳɵÄpoIFN-!1³ÉÊìµ°°×±àÂë»ùÒò¹¹½¨pRLC/DH5!±í´ïϵͳ¡£±í´ï²úÎïÒÔ°üº­ÌåÐÎʽ´æÔÚ, °üº­Ìå¾­±äÐÔ¡¢¸´ÐԺʹ¿»¯»ñµÃµÄÖØ×époIFN-!1ÔÚMDBK/VSVϵͳÉϵĿ¹²¡¶¾»îÐÔԼΪ6.4×106 U/mg¡£Ð»º£ÑàµÈ[30]½«Öí¸ÉÈÅËØ!µÄ»ùÒòÑÇ¿Ë¡µ½Ô­ºË±í´ïÔØÌåpET-28a, ¹¹½¨ÁËÖØ×é±í´ïÖÊÁ£pE-TIFN-!¡£¾­¹ýSDS-PAGEµ°°×ÖʵçÓ¾, ²âµÃ±í´ïµ°°×µÄÏà¶Ô·Ö×ÓÖÊÁ¿Ô¼Îª2.65×104, Æ俹²¡¶¾»îÐÔ²»Ïê¡£XIAµÈ[4]¹¹½¨pQE30/PoIFN-!c/M15 (pREP4) ±í´ïϵͳ, ±í´ïµÄrPoIFN-!ÒÔ°üº­ÌåÐÎʽ´æÔÚ, ¾­²¿·Ö´¿»¯²¢³ä·Ö¸´ÐÔºó, ÓÃϸ°û²¡±äÒÖÖÆ·¨²â¶¨rPoIFN-!ÔÚMDBKϸ°ûÉÏ¿¹ÂËÅÝÐÔ¿ÚÑײ¡¶¾ (VSV) »îÐÔ´ï1×108 IU/mL¡£

¡¡¡¡ÁõռͨµÈ[31,32,33]¹¹½¨ÁËPGEX-4T-1/BL21±í´ïϵͳ, ±í´ï²úÎïN-¶Ë´øGSTÈںϵ°°×, ÇÒÒÔ°üº­ÌåÐÎʽ´æÔÚ, ¾­±äÐÔ¡¢¸´ÐÔ´¦Àíºó, ÔÚVeorϸ°ûÉÏ¿¹VSVµÄ»îÐÔΪ2.24×103 U/mg¡£Áí¹¹½¨ÁËpET-43.1a-C (+) /BL21±í´ïϵͳ, ±í´ïµÄÈںϵ°°×ÒÔ¿ÉÈÜÐÔÐÎʽ´æÔÚ¡£±í´ï²úÎïÔ¼Õ¼¾úÌå×ܵ°°×µÄ29.8%¡£ÀîÎĻԵÈ[34]È«»ùÒòºÏ³ÉµÃµ½±àÂëÒ°Öí¸ÉÈÅËØ!³ÉÊìëĵĻùÒò, ¹¹½¨ÁËpWL/DH5!±í´ïϵͳ, ÖØ×éÒ°ÖíIFN!±í´ïÁ¿´óÓÚ25%¡£¸´ÐÔ´¿»¯ºóÖØ×éµ°°×ÔÚWISH/VSVÉϵĻîÐÔΪ4.45×106 IU/mg¡£ãÆÈôDZµÈ[35]¹¹½¨ÁËpQE30/PolFN-!/JM109±í´ïϵͳ, ±í´ïµÄÈÚºÏÖØ×éÖí¸ÉÈÅËØ!µ°°×ͨ¹ýÄòËرäÐÔ¡¢µÍŨ¶Èµ°°×¸´ÐÔÒº¸´ÐÔ¡¢PBSÈÜҺ͸ÎöµÈ²½Öè½øÐд¿»¯, µ°°×´¿¶ÈÔÚ95%ÒÔÉÏ, ´¿»¯µÄrPoIFN-!µ°°×ÔÚPK15ϸ°ûÉÏ¿¹VSV²¡¶¾»îÐÔµ¥Î»Îª1.448 2×104 IU/mL (5.2×106 IU/mg) , ÔÚMarc-145ϸ°ûÉÏÄÜÍêÈ«ÒÖÖƸßÖ²¡ÐÔPRRSVÔöÖ³ËùÐèµÄrPoIFN-!µ°°××îµÍÓÐЧ¼ÁÁ¿Îª640 U/mL (2.3×104 U/mg) ¡£³Âѩ÷µÈ[36]¹¹½¨ÁËpET-His/PoIFN-!/Rosetta (DE3) ±í´ïϵͳ, ±í´ï²úÎï¾­°üº­ÌåÏ´µÓ¡¢¹ýÖù´¿»¯ºó, µ°°×´¿¶ÈÄÜ´ï90%ÒÔÉÏ¡£ÔÚMarc-145/PRRSV¡¢Marc-145/VSV¡¢PK-15/VSV¡¢Vero/VSV¡¢MDBK/VSVϵͳÉϵĿ¹²¡¶¾»îÐÔ·Ö±ðΪ2.46×107 U/mg¡¢4.32×105 U/mg¡¢8.45×105 U/mg¡¢2.45×105 U/mg¡¢2.68×107 U/mg¡£¸ßÃ÷µÈ[37]²ÉÓÃRT-PCR´ÓÖíÆ¢ÁÜ°Íϸ°ûÖÐÀ©Ôö³öÖíIFN!»ùÒò, ÒÔpPROExHTaΪÔØÌå¹¹½¨Á˱í´ïÖØ×éÖÊÁ£, ת»¯ËÞÖ÷¾úBL21, ¾­IPTGÓÕµ¼»ñµÃÁ˱í´ï¡£¸ÃÖØ×éµ°°×ÒÔ°üº­ÌåÐÎʽ´æÔÚ, ²ÉÓÃNi-Ni½ðÊôòüºÏÇ׺ͲãÎö·½·¨´¿»¯, Æä´¿¶È´ïµ½80%ÒÔÉÏ, °üº­Ìå¾­¸´ÐÔºó, ÔÚWISH/VSVϵͳÉÏ, ÆäÏ¡ÊͶÈСÓÚ1¡Ã103ʱ²ÅÓп¹²¡¶¾»îÐÔ¡£¼Ö×ÔÎĵÈ[38]¹¹½¨ÁËpET28-PolFN-!/BL21±í´ïϵͳ, ±í´ï²úÎïÖ÷ÒªÒÔ°üº­ÌåÐÎʽ´æÔÚ, ´¿»¯ºóµÄÄ¿µÄµ°°×´¿¶ÈԼΪ90%, Æä»îÐÔԼΪ1.67×106 U/mg¡£

¡¡¡¡ÏÄ¿¡±£µÈ[39]ÌáÈ¡Öí¸ÎÔàϸ°û»ùÒò×éDNA, PCRÀ©ÔöÖí¸ÉÈÅËØ! (PoIFN-!) »ùÒò, ¿Ë¡µ½pGEX-5X-1ÔØÌåÉÏ, ת»¯ÈëE.coli BL21, GSTÇ׺ͲãÎö´¿»¯, Hep-2/VSVϵͳÉϵζ¨Ð§¼Û¡£½á¹û´øÓÐGST±ê¼ÇµÄrpoIFN-!ÄܸßЧ±í´ï, ¸ÃrPoIFN-!ÔÚHep-2/VSVϵͳÉϵĿ¹²¡¶¾»îÐÔΪ1.1×107 IU/mg¡£ËÎÕñÍþµÈ[40]ÒÔµ°°×ÖÊ×ÔÇиîÔª¼þÄÚº¬ëÄ (Intein) Ìæ´úµ°°×ø, ²¢ÒÔϸ¾ú×ÔÉí²úÉúµÄ¾ÛôÇ»ù¶¡Ëáõ¥ (PHB) ¿ÅÁ£Ìæ´úÇ׺ÍÅä»ù, ¹¹½¨ÁËÐÂÐÍÄÚº¬ëĽ鵼PHBµÄPoIFN-!±í´ïºÍ´¿»¯Ìåϵ, µ±ÓÕµ¼×ÔÇиӦζÈΪ20¡æ¡¢pH=6.5¡¢·´Ó¦Ê±¼äΪ24~36hʱ, ¿ÉÒÔʵÏÖÄÚº¬ëÄC¶Ë¸ßЧ×ÔÇиî, ´¿»¯³öµÄPoIFN-!²úÁ¿Îª20~30 mg/L¡£Íò²©µÈ[41]À©ÔöÖí¸ÉÈÅËØ!»ùÒò, ¿Ë¡ÖÁÔ­ºË±í´ïÔØÌåpET-28aÖÐ, ¹¹½¨Ô­ºË±í´ïÔØÌåpET-IFN-!, ½«pET-IFN-!ת»¯ÖÁBL21½øÐбí´ï¡£±í´ïµÄÖí!¸ÉÈÅËØÔÚPAMϸ°ûÉÏ¿¹PRRSV»îÐÔΪ1.13×106 U/mg¡£ÑîÓÀʤµÈ[42]¸ù¾ÝÖí¸ÉÈÅËØ!1 (PoIFN-!1) µÄÈ«»ùÒòÐòÁÐ (EU364896) Éè¼ÆºÏ³É1¶ÔÌØÒìÒýÎï, ͨ¹ýRT-PCR´ÓÈýÔªÔÓ½»×ÐÖíÍâÖÜѪÁÜ°Íϸ°ûÀ©Ôö³öpoIFN-!1È«»ùÒò, ½«Æ䶨Ïò¿Ë¡µ½Ô­ºË±í´ïÔØÌåpGEX-6P-1ÖÐ, ¹¹½¨ÖØ×é±í´ïÔØÌåpGEX-6P-poIFN-!1, ת»¯´ó³¦¸Ë¾úBL21 (DE3) , ¿É±í´ïÏà¶Ô·Ö×ÓÖÊÁ¿Ô¼4.6×104µÄÈںϵ°°× (GST-PoIFN-!1) , Ä¿µÄµ°°×ÒÔ°üº­ÌåÐÎʽ±í´ï¡£ÕÔΰ¸ëµÈ[43]¹¹½¨pET-30-IFN-!/BL21±í´ïϵͳ, ±í´ï²úÎïÖ÷ÒªÒÔ°üº­ÌåÐÎʽ´æÔÚ, °üº­Ìåµ°°×¾­±äÐÔ¡¢¸´ÐÔºó, ¾­Ni2+-NTAÇ׺ͲãÎö´¿»¯, »ñµÃ¸ß´¿¶ÈÖØ×éÖíIFN-!, ¿¹ÐÇ×´²¡¶¾¸´ÖƵĻîÐÔΪ3.15×103 U/mg¡£ãÆÀö»ÔµÈ[44]½«Öí¸ÉÈÅËØ!¿Ë¡ÈëÔ­ºË±í´ïÔØÌåpPROExHTa, ת»¯BL21, IPTGÓÕµ¼±í´ï, ±í´ï²úÎïÖ÷ÒªÒÔ°üº­ÌåµÄÐÎʽ´æÔÚ, °üº­Ìå¾­±äÐÔ¡¢¸´ÐÔ, Æä»îÐÔΪ2 900IU/mg¡£Ö£ÃùµÈ[45]¹¹½¨ÁËpET30a/BL21 (DE3) ±í´ïϵͳ, ÒÔN-Ê®¶þÍé»ù¼¡°±ËáÄÆ (SKL) ×÷Ϊ±äÐÔ¼Á, °üº­Ìå±äÐÔÈܽâºó²ÉÓÃÏ¡ÊÍ·¨½øÐи´ÐÔ¡£ÔÚMarc-145¿¹PRRSVºÍVSVµÄ»îÐÔ·Ö±ðΪ11.3×106U/mgºÍ2.35×106 U/mg, ÔÚPK-15ϸ°ûÉÏ, ¿¹PRRSVºÍVSVµÄ»îÐÔ·Ö±ðΪ18.2×106 U/mgºÍ4.31×106 U/mg¡£×î½üÎÒÃǵ¥Î»¹¹½¨ÁËÒ»Ì×еĴ󳦸˾ú±í´ïϵͳ, ʵÏÖÁËÖíIFN-!Ôڴ󳦸˾úµÄ¸ßˮƽ¿ÉÈܱí´ï, ¾­Ç׺ͲãÎöÒ»²½·¨´¿»¯, Æä´¿¶È´ïµ½90%ÒÔÉÏ, ´¿»¯³öµÄPoIFN-!²úÁ¿Îª100mg/L, ÔÚPK-15/VSVϵͳÉϵĿ¹²¡¶¾»îÐÔԼΪ1.0×108 U/mg, Æä²úÁ¿ºÍ¿¹²¡¶¾»îÐÔ¾ù¸ßÓÚÏÖÓб¨µÀ, ΪÆä²úÒµ»¯Éú²úºÍÓ¦Óõ춨ÁË»ù´¡¡£

¡¡¡¡2.2 Öí¸ÉÈÅËØ!ÔÚ½Íĸ±í´ïϵͳÖеıí´ï

¡¡¡¡»Æº£µÈ[46]½«Öí¸ÉÈÅËØ! (PoIFN-!) »ùÒò¿Ë¡Èë±Ï³à½Íĸ·ÖÃÚÐͱí´ïÔØÌåpPICZ!AÖÐ, µçת»¯±Ï³à½ÍĸKM71H¾úÖê, ¿¹ÉúËØzeocinŨ¶ÈÌݶÈɸѡ¸ß¿¹ÐÔת»¯×Ó, ÒÔPCR¼ø¶¨ÑôÐÔÖØ×é¾úÖê, Óü״¼ÓÕµ¼±í´ï¡£±í´ïÁ¿Îª0.45mg/mL, ¾­WISH/VSV¼ì²â±í´ï²úÎïµÄ¿¹²¡¶¾»îÐÔΪ5.6×104 IU/mg¡£¸ðÀöµÈ[47]½«Öí¸ÉÈÅËØ!»ùÒò¿Ë¡Èë±Ï³à½Íĸ·ÖÃÚÐͱí´ïÔØÌåpPICZ!AÖÐ, µçת»¯±Ï³à½ÍĸKM71H¾úÖê, ÒÔPCR¼ø¶¨ÑôÐÔÖØ×é¾úÖꡣɸѡ³öµÄ¸ß¿½±´ÖØ×é¾úÖê·Ö±ðͨ¹ýBMGY/BMMYÅàÑø»ùºÍYPGÅàÑø»ù, Óü״¼ÓÕµ¼±í´ïSDS-PAGEºÍWestern blotÓ¡¼£ÔÓ½»½á¹û֤ʵ, ±í´ï²úÎïΪÖØ×éPoIFN-!Èںϵ°°×, ¾­Ï¸°û¶¾ÐÔÊÔÑé¼ì²â (WISH/VSVϵͳ) , ±í´ï²úÎïµÄ¿¹²¡¶¾»îÐÔΪ4.1×106 IU/mL¡£Ò¦ÇåÏÀµÈ[48]½«±àÂë÷ɽÖí¸ÉÈÅËØ!³ÉÊìµ°°×»ùÒò (mPoIFN-!, 501bp) ÑÇ¿Ë¡µ½º¬·ÖÃÚÐźÅëÄÐòÁеıϳà½Íĸ±í´ïÔØÌåpPIC9KÖÐ, ¹¹½¨³É·ÖÃÚÐÍÖØ×é±í´ïÔØÌåpPIC9K-mPoIFN-!¡£×ª»¯Èë±Ï³à½Íĸ¾úÖêGS115, ±í´ï²úÎïÏà¶Ô·Ö×ÓÖÊÁ¿Ô¼Îª2.0×104, ÔÚGS115Öеıí´ïÁ¿Ô¼Îª40mg/L, Õ¼GS115±í´ïµÄ¿É·ÖÃÚÐÍ×ܵ°°×µÄ40.1%¡£¶Ô±í´ï²úÎï½øÐÐÀí»¯·ÖÎö·¢ÏÖ, ÖØ×é½Íĸ¾ú±í´ïµÄµ°°×ÄÍËá (pH 2) , ¶ÔÈÈ (56¡æ) ²¿·ÖÃô¸Ð, ²¢Äܱ»ÌØÒìÐÔ¿¹Öí¸ÉÈÅËØ!¿¹ÌåÖкͶø²»Ó뿹Öí¸ÉÈÅËØ#¿¹Ìå·´Ó¦¡£rPoIFN-!ÔÚMDBKÖеĿ¹VSV±È»îÐÔΪ8.0×106U/mg¡£

¡¡¡¡ÕÅ´æµÈ[49]½«PCRÀ©ÔöµÄPoIFN-!»ùÒò²åÈëpPIC9k, ¹¹½¨Á˱í´ïתÒÆÔØÌåpPIC9k/PoIFN-!, µçת»¯±Ï³à½ÍĸGS115¾úÖê, ÖØ×é¾úÖê¾­BMMYÅàÑø»ùÓÕµ¼ºóÉÏÇåÖÐÓÐÄ¿µÄµ°°×, ±í´ïÁ¿´ï136mg/L¡£±í´ï²úÎï¾­¹ýSP-SepharoseÑôÀë×Ó½»»»²ãÎö, ¿ÉÒԵõ½´¿¶È½Ï¸ßµÄrPoIFN-!, ´¿»¯²úÎïÔÚMDBKϸ°ûÉÏÒÖÖÆVSVµÄ»îÐԸߴï2.27×108 U/mg¡£ÕÅÀÙµÈ[50]ÓÃRT-PCR·½·¨»ñµÃÖí¸ÉÈÅËØ!»ùÒò, ½«¸Ã»ùÒòÓëÕæºË±í´ïÖÊÁ£pPIC9KÁ¬½Ó, ²¢µçתÈë±Ï³à½ÍĸGS115¾úÖÐ, ¾­¼×´¼ÓÕµ¼±í´ïºó, SDS PAGEµçÓ¾¼ì²âIFN-!µ°°×±í´ïÏà¶Ô·Ö×ÓÖÊÁ¿Ô¼Îª1.9×104µÄµ°°×ÖÊ¡£Áõ½¡µÈ[51]¸ù¾Ý±Ï³à½ÍĸPichia pastoris±í´ïϵͳ¶ÔÓÚÃÜÂë×ÓµÄÆ«ÊÈÐÔ, ½«È¥³ýÐźÅëĵÄÖí¸ÉÈÅËØ! (PoIFN-!) »ùÒòÖØÐÂÉè¼Æ¸ÄÔì²¢ºÏ³ÉÒ»¶ÎеĺËÜÕËáÐòÁÐ, ÖÃÓڱϳà½Íĸ¾ú!Òò×Ó·ÖÃÚÐźŵÄDNAÐòÁкó, ¹¹½¨³ÉpPICZAC-PoIFN-!·ÖÃÚÐÍÖØ×é±í´ïÔØÌå, µçת»¯½øÈëÒ°ÉúÐͱϳà½Íĸ¾úX-33ÖÐ, ¾­Zeocin TM¿¹ÐÔɸѡºó»ñµÃ´óÁ¿¶à¿½±´ÖØ×é×Ó, Ëù»ñµÃµÄÖØ×é×ÓÄܹ»·ÖÃÚ±í´ï³öÏà¶Ô·Ö×ÓÖÊÁ¿Ô¼Îª1.9×104µÄPoIFN-!ÌØÒìµ°°×, ÆäÓÐЧµ°°×±í´ïÁ¿½Ï¸ß, ´ï54.105mg/L¡£¾­Vero-VSVϵͳ²â¶¨PoIFN-!Ч¼Û´ïµ½5.87×107 U/L¡£

¡¡¡¡2.3 Öí¸ÉÈÅËØ!ÔÚÆäËü±í´ïϵͳÖеıí´ï

¡¡¡¡ÍõÑå±òµÈ[52]Ó¦ÓÃBac-to-Bac¸Ë×´²¡¶¾/À¥³æϸ°û±í´ïϵͳ, ½«±àÂëÖí¸ÉÈÅËØαºÍγ³ÉÊìµ°°×»ùÒò²åÈ빩ÌåÖÊÁ£pFastBacDual, ·Ö±ðÖÃÓÚPHºÍP10Æô¶¯×Ó¿ØÖÆÏÂ, ÒýÈë·äËØÐźÅëÄ (honeybee melittin signal peptide, HBM) »ùÒòÈ¡´úÖí¸ÉÈÅËØαºÍγÔ­ÓÐÐźÅëÄ»ùÒòÒÔʵÏÖ·ÖÃÚÐͱí´ï, ²¢ÔÚC¶Ë·Ö±ðÈÚºÏ6¸ö×é°±Ëá±êÇ©ÒÔÀûÓÚ´¿»¯¡£½«¹¹½¨ÖÊÁ£×ª»¯DH10¸ÐÊÜ̬ϸ°û½øÐÐͬԴÖØ×é, »ñµÃÖØ×é´©ËóÖÊÁ£Bacmid, תȾ¶ÔÊýÉú³¤ÆÚµÄSf9À¥³æϸ°û»ñµÃÖØ×é¸Ë×´²¡¶¾¡£ÖØ×é¸Ë×´²¡¶¾¸ÐȾÀ¥³æϸ°û, Öí¸ÉÈÅËØαºÍγÖØ×éµ°°×ÔÚÖØ×é¸Ë×´²¡¶¾¸ÐȾµÄÀ¥³æϸ°ûÖоù»ñµÃ±í´ï, ±í´ï²úÎïÖ÷Òª·Ö²¼ÔÚÅàÑøÉÏÇåÒºÖС£Í¨¹ýÔÚÖíÉöϸ°û (PK-15) ÉÏÒÖÖÆË®ÅÝÐÔ¿ÚÑײ¡¶¾ (VSV) Ö²¡±ä×÷Óüì²â, À¥³æϸ°ûÉÏÇåµÄ¿¹²¡¶¾Ð§¼Û´ïµ½3.24×107 U/mL¡£ÔÚMarc-145ϸ°û, À¥³æϸ°ûÉÏÇåÒº¾­2-11Ï¡ÊÍÄܹ»ÒÖÖÆ100¸öTCID50µÄPRRSVµÄÖÂϸ°û²¡±ä×÷Óá£

¡¡¡¡3 Öí¸ÉÈÅËØ!µÄÓ¦ÓÃÑо¿

¡¡¡¡3.1 ×÷Ϊ¿¹²¡¶¾ÖƼÁÔÚÖí²¡¶¾²¡·ÀÖÎÉϵÄÓ¦ÓÃ

¡¡¡¡CUMMINSµÈ[53]ÔÚÖíȺ±©·¢TGEʱ, ½«1~12ÈÕÁäµÄ×ÐÖí·ÖΪ4×é, ·Ö±ðÁ¬Ðø4d¿Ú·þ0¡¢1¡¢10¡¢20IUµÄnHuIFN-!, ½á¹û¿Ú·þ¸ÉÈÅËØ×ÐÖíµÄ´æ»îÂÊÃ÷ÏÔ¸ßÓÚ¶ÔÕÕ×é¡£CHINSANGARAMµÈ[13]¹¹½¨Á˱í´ïÖí¸ÉÈÅËØ!µÄÖØ×éÏÙ²¡¶¾, ¸øÖí½ÓÖÖ109PFUÖØ×éÏÙ²¡¶¾, 24hºóÓÃFMDVÇ¿¶¾¹¥»÷, ÊÔÑéÖíûÓÐÁÙ´²Ö¢×´ºÍ²¡¶¾ÑªÖ¢, ҲûÓмì²âµ½Õë¶ÔFMDV·Ç½á¹¹µ°°×µÄ¿¹Ìå, »ñµÃÍêÈ«±£»¤¡£á¯Â·µÈ[54]²ÉÓñϳà½Íĸ±í´ïϵͳ±í´ïµÄÖí¸ÉÈÅËØ!·¢½Í¹¤ÒÕÖÐÊÔ²úÆ·, °´ÕÕÅ©Òµ²¿°ä²¼µÄ¡¶¸ßÖ²¡ÐÔÖí·±Ö³ÓëºôÎü×ÛºÏÕ÷·ÀÖμ¼Êõ¹æ·¶¡·½øÐÐÖÎÁƲ¡¶¾ÐÔÖ퓸ßÈȲ¡”ÁÙ´²¹Û²ì, ¶ÔÈ·ÕïΪ¸ßÖ²¡ÐÔPRRSµÄ²¡ÖíËæ»úÑ¡³ö²¡³Ì½ÏÖصÄ8Í·×÷ΪÖÎÁÆÊÔÑé×é, ÆäÓà2Í·Ö¢×´½ÏÇáµÄÉèΪ¶ÔÕÕ×é¡£ÊÔÑé×é¸ÉÈÅËصÄÓÃÁ¿5mL/ (Í··d) , ¾±²¿¼¡Èâ×¢Éä, Á¬ÓÃ6d¡£´ËÍâ, Óë¶ÔÕÕ×éÏàͬµÄ·½·¨ºÍ¼ÁÁ¿Ê¹Óÿ¹¾úËصÈÅäºÏÖÎÁÆÒ©Îï¡£¶ÔÕÕ×é¾±²¿¼¡Èâ×¢Éä10%¶÷ŵɳÐÇ×¢ÉäÒº5mL/ (Í··d) , Íâ¼ÓÍ·æ߽𷽡¢°¢ÄªÎ÷ÁÖ·Û°èÁϺÍÇ¿Á¦°Ý¹ÌÊæÒûË®, Á¬ÓÃ6d¡£¶ÔÕÕ×éÓëÖÎÁÆ×éЧ¹û²îÒìÏÔÖø, ÊÔÑé×éÖÎÓúÂÊ´ï87.5%¡£á¯Â·µÈ[54]¶ÔÈ·ÕïΪ¸ßÖ²¡ÐÔPRRSµÄ²¡ÖíËæ»ú×ÐÖí·Ö³É3×é, Öí¸ÉÈÅËØ! (l.37×109 IU/mL) µÄÓÃÁ¿·Ö±ðΪ0.5¡¢1.0¡¢1.5mL/ (Í··d) , ¾±²¿¼¡Èâ×¢Éä, Á¬ÓÃ3~6d;³ÉÖíÒ²·Ö³É3×é, ¸ÉÈÅËصÄÓÃÁ¿·Ö±ðΪ1.0¡¢1.5¡¢2.0mL/ (Í··d) , ¾±²¿¼¡Èâ×¢Éä, Á¬ÓÃ3~6d¡£Í¬Ê±²ÉÓÃÓë¶ÔÕÕ×éÏàͬµÄ·½·¨ºÍ¼ÁÁ¿Ê¹Óÿ¹¾úËØ¡£Æ½¾ùÖÎÓúÂÊÔÚ81%ÒÔÉÏ¡£

¡¡¡¡ÐÜÖÒÁ¼µÈ[55]ÒÔÎ人Êкͽ­ººÆ½Ô­2¸ö¹æÄ£Öí³¡·¢ÉúÖíÎÁ¡¢ÖíÀ¶¶ú²¡µÈ²¡¶¾ÐÔ´«È¾²¡Îª¶ÔÏó, ÓÃÖí»ùÒò¹¤³Ì¸´ºÏ¸ÉÈÅËØÅäºÏ³£¹æÒ©Îï½øÐÐÁËÔ¤·ÀºÍÖÎÁÆЧ¹ûÊÔÑé¡£ÖÎÁÆÊÔÑéÑ¡ÔñÁÙ´²·¢²¡Öí½øÐÐÁÆЧ¹Û²ì, AÖí³¡Ñ¡ÓÃ196Í··¢²¡×ÐÖí¼¡×¢àçß»æßÍõºÍ»ÆÜζàÌÇ×¢ÉäÒº, ÓÃÁ¿·Ö±ðΪ40~50 mg/kgÌåÖغÍ3~5mL/Í·, Á¬ÓÃ3~5d, ͬʱ¼¡×¢Öí»ùÒò¹¤³Ì¸´ºÏ¸ÉÈÅËØ2mL/Í·, 1´Î/d, Á¬ÓÃ3d;BÖí³¡Ñ¡ÓÃ324Í··¢²¡×ÐÖí¼¡×¢·úÁ¦¼ÑºÍ»ÆÜζàÌÇ×¢ÉäÒº, ÓÃÁ¿·Ö±ðΪ0.1mL/kgÌåÖغÍ3~5mL/Í·, Á¬ÓÃ3~5 dͬʱ¼¡×¢Öí»ùÒò¹¤³Ì¸´ºÏ¸ÉÈÅËØ2mL/Í·, 1´Î/d, Á¬ÓÃ3d;A¡¢BÁ½Öí³¡·Ö±ðÉè¶ÔÕÕ×é, ¶ÔÕÕ×é²»×¢ÉäÖí¸ÉÈÅËØ, ÆäËûÖÎÁÆÇé¿öÏàͬ, ¼Ç¼²¡ÖíËÀÍö¼°¿µ¸´Çé¿ö¡£Ô¤·ÀÊÔÑé·Ö±ðËæ»úÑ¡Ôñ¸÷Öí³¡Î´·¢²¡²¸Èé×ÐÖí, ¼¡×¢Öí¸ÉÈÅËØ3~4´Î, 2mL/Í·, ÿ7~8dÔ¤·À×¢Éä1´Î, ¶ÔÕÕ×é²»×¢ÉäÖí¸ÉÈÅËØ, ͳ¼Æ·¢²¡¼°³É»î×ÐÖíÊý, ÊÔÑé×éºÍ¶ÔÕÕ×éµÄÃâÒߺͱ£½¡¾ùÕý³£½øÐС£½á¹û¸ÉÈÅËØÅäºÏ³£¹æÊÞÒ©ÖÎÁÆ×ÜÓÐЧÂÊ·Ö±ðΪ87.2%¡¢84.6%, Óë¶ÔÕÕ×é×ÜÓÐЧÂÊ29.15%¡¢26.1%Ïà±È½Ï, ²îÒ켫ÏÔÖø (P<0.01) ;¸ÉÈÅËضԲ¡¶¾ÐÔ¼²²¡Ô¤·ÀÊÔÑé×ÐÖí³É»îÂÊ·Ö±ðΪ95.8%¡¢93.6%, Óë¶ÔÕÕ×é³É»îÂÊ54.7%¡¢68.1%Ïà±È½Ï, ²îÒ켫ÏÔÖø (P<0.01) ¡£

¡¡¡¡á¯Â·µÈ[56]Ñ¡Ôñ¹ã¶«ËÄ»áijÖí³¡40Í·¶ÏÄÌ×ÐÖíΪ¹Û²ì¶ÔÏó, °´ÊÔÑéÒªÇóËæ»ú·Ö³É3¸ö×é, ȡƽ¾ùÌåÖØ8.39kgµÄ14ͷΪ¶ÔÕÕ×é, ÁíÍâƽ¾ùÌåÖØΪ6.85ºÍ7.04kgµÄ¸÷13Í··Ö±ðΪÊÔÑé1¡¢2×é¡£¹º½ø¹©ÊÔÑé¶ÏÄÌ×ÐÖí, µÚ2ÌìÉÏÎçÊÔÑé×é·Ö±ð°´ÊÔÑé1×éΪ1 mL/Í· (≥8.3×106 IU/kg) ¡¢ÊÔÑé2×éΪ2mL/Í· (≥1.6×107 IU/kg) ¼¡Èâ×¢ÉäPoIFN-!×¢ÉäÒº¡£ÊÔÑé¹Û²ì35d¡£ÊÔÑé1¡¢2×éÓë¶ÔÕÕ×éÏà±È½ÏÁÏÖرȷֱ𽵵Í6.3ºÍ17.23°Ù·Öµã, ƽ¾ùÈÕÔöÖØÂÊ·Ö±ð¸Ä±äÁË3.69ºÍ24.85°Ù·Öµã, ³É»îÂÊ·Ö±ðÌá¸ßÁË6.6ºÍ14.3°Ù·Öµã, ¸¹ÐºÂʷֱ𽵵ÍÁË11.5ºÍ26.9°Ù·Öµã, ¼²²¡×Ü·ÀÖÎÂÊ·Ö±ðÌá¸ßÁË40.1ºÍ55.49°Ù·Öµã;ÊÔÑé¹Û²ìÆÚ¼ä, ¶ÔÕÕ×éÕï¶ÏΪÀ¶¶ú²¡µÄ4Àý, ËÀÍö1Àý, ÊÔÑé×éÔòûÓз¢ÉúÀ¶¶ú²¡Àý¡£±íÃ÷Öí¸ÉÈÅËØ!¶Ô×ÐÖíµÄÉú³¤ÓÐÁ¼ºÃµÄ´Ù½ø×÷ÓÃ, ¾ßÓÐÏÔÖøµÄ½ô¼±Ô¤·À²¡¶¾ÐÔ¼²²¡Ð§¹û¡£´ÞÉнðµÈ[57]ÀûÓÃÏÙ²¡¶¾±í´ïϵͳ±í´ïÖí¸ÉÈÅËØ!, º¬ÓиÉÈÅËز»µÍÓÚ1 000ÍòU/mL, 5mL/Æ¿, 5 000ÍòU/Æ¿¡£Ê¹Ó÷½·¨ÊǼ¡Èâ×¢Éä¡£ÌåÖØ≤50kg, 0.5 mL/Í·;ÌåÖØ50kgÒÔÉÏ, 1.0mL/Í·¡£×¢Éä1´Î/ (Í··d) ;²¡ÖØÕß¿É×¢Éä2´Î/d, Á¬Ðø3~5d¡£¶ÔÁÙ´²·¢Éú¿ÚÌãÒß¡¢À¶¶ú²¡µÈ²¡¶¾²¡µÄÖíȺ¾ßÓÐÃ÷ÏÔµÄÖÎÁÆЧ¹û, ûÓøÉÈÅËØÖÎÁƵÄËÀÍöÂʸߡ¢ÖÎÓúÂʵ͡¢·¢²¡³ÖÐøÆÚ³¤¡£

¡¡¡¡Íõµ¤[58]ÀûÓÃPET32a/BL21±í´ïϵͳ±í´ïÁËÖí!¸ÉÈÅËØ, ÔÚMarc-145ϸ°ûÉϲⶨÖØ×éÖí¸ÉÈÅËØ!¿¹PRRSVµÄ²¡¶¾»îÐÔΪ5.0×103 U/mg¡£½«¾­¹ýʵÑéÊÒÈ·ÕïΪÖíÔ²»·²¡¶¾¡¢À¶¶ú²¡¶¾ºÍ¸±ÖíÊÈѪ¸Ë¾ú»ìºÏ¸ÐȾµÄ20Í·Öí½øÐиôÀë, Ëæ»ú·Ö³É2×é, 10Í·/×é, µÚ1×éÓøÉÈÅËؾ±²¿¼¡Èâ×¢Éä, 10U/kg, ¶ÔÖ¢ÖÎÁÆÓÃ5%ÆÏÌÑÌÇ¡¢ÐÂÐÍÀ¶Ô²Î±É¢ (Ö÷Òª³É·Ö:»ÆÜΡ¢Ì컨·Û¡¢°Ü½´²Ý¡¢°åÀ¶¸ù¡¢ÔÆÖ¥¶àÌÇ) °èÁÏ, À­Ï¡Ó¦¼¤¿µÒûË®, ÑÏÖصļ¡Èâ×¢Éä±ÌѪ½£;µÚ2×éÖ»ÓÃÒÔÉÏÒ©Îï½øÐÐÖÎÁÆ, ²»ÓøÉÈÅËØ×¢Éä¡£µÚ1×é·¢²¡Öí´¦·½Ð§¹ûÊ®·ÖÀíÏë, ÓÃÒ©µÚ1d, ¾«ÉñʳÓûÃ÷ÏÔºÃת, µÚ3Ì쾫Éñ¡¢Ê³Óû¡¢Ìåλù±¾»Ö¸´Õý³£, µÚ5Ìì³ýÓÐ1Í·Öí²¡Çé½ÏÖز»Ê³, ÖÎÁƵĵÚ3ÌìËÀÍöÍâ, ÆäÓà9Í·¾ù¿µ¸´, ÁÆЧ90%¡£µÚ2×éÓÃÒ©2d, ÓÐ7Í·Öí¾«Éñ¡¢Ê³Óû¡¢ÌåκÃת, µ«ÈÔÓÐ3Í·Öí¾«Éñ²î, Á¬ÐøÓÃÒ©5d, Í£Ò©ºóÈÔÓÐ2Í·Öí¸´·¢, ÓÖ²ÉÓÃÍ·æßàçß»ÄÆ (¹þÒ©¼¯ÍÅÊÞÒ©³§) 0.5g/Í·, ¼¡Èâ×¢Éä, 1´Î/d, Á¬ÓÃ5d, ËÀÌÔ3Í·, ÆäÓà7Í·¿µ¸´¡£ÒÔÉϱ¨µÀ˵Ã÷, Öí¸ÉÈÅËØ!¶ÔÖí´«È¾ÐÔ賦Ñס¢¿ÚÌãÒß¡¢Öí·±Ö³ÓëºôÎü×ÛºÏÕ÷ºÍÖíÎÁµÈ²¡¶¾ÐÔ¼²²¡¾ßÓнϺõķÀÖÎЧ¹û, ÖµµÃÍƹ㡣

¡¡¡¡3.2 ×÷ΪÃâÒß×ô¼Á, ÔÚÐÂÐÍ»ùÒò¹¤³ÌÒßÃçÉϵÄÓ¦ÓÃ

¡¡¡¡CHENGµÈ[17]Ñо¿ÁËÖí¸ÉÈÅËØ!¶ÔÖí¿ÚÌãÒßÖØ×éµ°°×ÒßÃçIgG-FMDVµÄÃâÒß×ô¼Á×÷Óá£IgG-FMDV°üº¬ÖíÃâÒßÇòµ°°×ÖØÁ´ºã¶¨ÇøºÍOÐÍ¿ÚÌãÒߵĿ¹Ô­ëÄ¡£½á¹û±íÃ÷Öí¸ÉÈÅËØ!ÁªºÏÖí¿ÚÌãÒßÖØ×éµ°°×ÒßÃçIgG-FMDV×é²úÉúÖкͿ¹ÌåµÄËٶȿì, ˮƽҲÃ÷ÏÔÌá¸ß, ¶ÔÇ¿¶¾¹¥»÷¿ÉÌṩÍêÈ«±£»¤, ÏÔʾ³öÏÔÖøµÄ×ô¼ÁЧӦ¡£²ÜÈð±øµÈ[59]½«½Íĸ±í´ïµÄPCV2Capµ°°×Åä±ÈÊÊÁ¿µÄÂÁ½º»òÖØ×éÖí¸ÉÈÅËØ!ÖƳÉÑǵ¥Î»ÒßÃç¡£30ÈÕÁä×ÐÖí·Ö±ð½ÓÖÖÂÁ½º×ô¼ÁÑǵ¥Î»ÒßÃçºÍÖí¸ÉÈÅËØ!×ô¼ÁÑǵ¥Î»ÒßÃç, ͬʱÉè¹¥¶¾¶ÔÕÕÓë¿Õ°×¶ÔÕÕ, Ê×Ãâºó21d¼ÓÇ¿ÃâÒß, ¶þÃâºó14dÓÃPCV2JSÖê¹¥¶¾¡£Öí¸ÉÈÅËØ!×ô¼ÁÑǵ¥Î»ÒßÃç×é×ÐÖíÃâÒߺó²úÉúµÄELISA¿¹ÌåºÍÖкͿ¹Ì嶼ÏÔÖø¸ßÓÚÂÁ½ºÑǵ¥Î»ÒßÃç×é×ÐÖí¡£¹¥¶¾¶ÔÕÕ×éµÄ4Í·×ÐÖí¹¥¶¾ºóÈ«¶¼²úÉúÁ˲¡¶¾ÑªÖ¢, ²¢Óнϳ¤Ê±¼äµÄ·¢ÈÈ;ÂÁ½ºÑǵ¥Î»ÒßÃç×é4Í·×ÐÖíÖÐÖ»ÓÐ1Í·×ÐÖí²úÉú²¡¶¾ÑªÖ¢, Ìí¼ÓÖí¸ÉÈÅËØ!Ñǵ¥Î»ÒßÃç×éµÄ×ÐÖí¹¥¶¾ºó¶¼Ã»ÓвúÉú²¡¶¾ÑªÖ¢¡£×ۺϷÖÎöÊÔÑéÖíµÄ²¡¶¾¸ÐȾ¡¢ÁÙ´²±íÏÖºÍÉú²úÐÔÄܵÈÇé¿ö, ±íÃ÷Capµ°°×Ñǵ¥Î»ÒßÃç¾ßÓÐÃâÒß±£»¤Ð§¹û, Öí¸ÉÈÅËØ!¿ÉÏÔÖøÔöÇ¿Capµ°°×Ñǵ¥Î»ÒßÃç½ÓÖÖ×ÐÖíµÄÌåÒºÃâÒß·´Ó¦, Ìá¸ßPCV-2Capµ°°×Ñǵ¥Î»ÒßÃçÃâÒß±£»¤Ð§¹û¡£

¡¡¡¡4 Ç°¾°Õ¹Íû

¡¡¡¡ÔÚµ±Ç°ÎÒ¹ú²¡Ô­±äÒìÖê²»¶Ï³öÏÖ, »ìºÏ»ò¼Ì·¢¸ÐȾÒѳɳ£Ì¬, ÁÙ´²Öí²¡Ô½À´Ô½ÄÑ·ÀÖεÄÐÎÊÆÏÂ, ¼±ÐèÑ°ÇóÒ»ÖÖ¸ßЧ¡¢°²È«ÒÔ¼°ÎÞ¶¾¸±×÷ÓõÄÐóÇݼ²²¡·ÀÖÎм¼Êõ¡¢Ð·½·¨ºÍвúÆ·¡£´óÁ¿Ñо¿±íÃ÷, Öí¸ÉÈÅËØ!ÊÇÒ»ÖÖ¾ßÓйãÀ«Ó¦ÓÃÇ°¾°µÄ¿¹²¡¶¾Ò©ÎĿǰÊг¡ÉÏʹÓÃ×î¶àµÄÊÇÖí°×ϸ°û¸ÉÈÅËØ, ÓÉËÄ´¨ÊÀºìÉúÎï¼¼ÊõÓÐÏÞ¹«Ë¾Í¨¹ýÓÕÉú·½·¨Éú²ú, ÓÚ1997Äê»ñµÃÅ©Òµ²¿ÐÂÊÞÒ©Ö¤Êé[ (97) ÐÂÊÞÒ©Ö¤×ÖµÚ01ºÅ]¡£ÖÁ½ñÉÐδÓлùÒò¹¤³ÌÖØ×éµÄÖí¸ÉÈÅËØ!»ñµÃÐÂÊÞÒ©Ö¤Êé, ҲδÓнø¿ÚµÄÖí¸ÉÈÅËØ!»ñµÃ½ø¿Ú×¢²áÖ¤Êé¡£Öí¸ÉÈÅËØ!Éú²ú³É±¾¸ß°ºÒ»Ö±ÊǸÉÈÅËØÔÚÊÞÒ½ÁÙ´²ÉÏÓ¦ÓõÄ×î´óÕÏ°­¡£µ«Ëæ×ÅÈËÃǶÔÖí¸ÉÈÅËØ!»ùÒò¹¤³Ì¼¼ÊõÑо¿µÄ²»¶ÏÉîÈë, ÈËÃǽ«»á¿ª·¢³ö¼Û¸ñµÍÁ®¡¢ÁÆЧºÃµÄ»ùÒò¹¤³ÌÖí¸ÉÈÅËØ!¡£2014Äê°²»Õ¾Å´¨ÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾É걨µÄÖØ×éÖí¸ÉÈÅËØ! (¶³¸ÉÐÍ) »ñµÃÁÙ´²ÊÔÑéÅúÎÄ (2014042) , 2017ÄêÕØÇì´ó»ªÅ©ÉúÎïÒ©Æ·ÓÐÏÞ¹«Ë¾µÈµ¥Î»É걨µÄ»ùÒò¹¤³ÌÖí!¸ÉÈÅËØ»ñµÃÁÙ´²ÊÔÑéÅúÎÄ (20170011) ¡£Ëæ×ÅÕâЩ»ùÒò¹¤³ÌÖí¸ÉÈÅËØ!µÄÉÏÊÐ, Öí²¡¶¾²¡µÄ·À¿Ø±Ø½«´øÀ´Ðµı仯¡£

¡¡¡¡²Î¿¼ÎÄÏ×
¡¡¡¡[1]POL J M, BROEKHUYSEN-DAVIES J M, WA-GENAAR F, et al.The influence of porcine recombinant interferon-alpha 1on pseudorabies virus infection of porcine nasal mucosa in vitro[J].Journal of General Virology, 1991, 72 (Pt4) :933-938.
¡¡¡¡[2]JORDAN L T, DERBYSHIRE J B.Antiviral activity of interferon against transmissible gastroenteritis virus in cell culture and ligated intestinal segments in neonatal pigs[J].Veterinary Microbiology, 1994, 38 (3) :263-276.
¡¡¡¡[3]JORDAN L T, DERBYSHIRE J B.Antiviral action of interferon-alpha against porcine Transmissible gastroenteritis virus[J].Veterinary Microbiology, 1995, 45 (1) :59-70.
¡¡¡¡[4]XIA C, DAN W, WEN-XUE W, et al.Cloning and expression of interferon-alpha/gamma from a domestic porcine breed and its effect on classical swine fever virus[J].Veterinary Immunology and Immunopathology, 2005, 104 (1) :81-89.
¡¡¡¡[5]ALBINA E, CARRAT C, CHARLEY B.Interferon-alpha response to swine arterivirus (PoAV) , the porcine reproductive and respiratory syndrome virus[J].Journal of Interferon and Cytokine Research, 1998, 18 (7) :485-490.
¡¡¡¡[6]BUDDAERT W, VAN R K, PENSAERT M.In vivo and in vitro interferon (IFN) studies with the porcine reproductive and respiratory syndrome virus (PRRSV) [J].Advances in Experimental Medicine and Biology, 1998, 440:461-467.
¡¡¡¡[7]LEE S M, SCHOMMER S K, KLEIBOEKER S B.Porcine reproductive and respiratory syndrome virus field isolates differ in in vitro interferon phenotypes[J].Veterinary Immunology and Immunopathology, 2004, 102:217-231.
¡¡¡¡[8]CHANG H W, JENG C R, LIU J J, et al.Reduction of porcine reproductive and respiratory syndrome virus (PRRSV) infection in swine alveolar macrophages by porcine circovirus 2 (PCV2) -induced interferon-alpha[J].Veterinary Microbiology, 2005, 108 (3) :167-177.
¡¡¡¡[9]BROCKMEIER S L, LAGER K M, GRUBMAN M J, et al.Adenovirus-mediated expression of interferon-alpha delays viral replication and reduces disease signs in swine challenged with porcine reproductive and respiratory syndrome virus[J].Viral Immunology, 2009, 22 (3) :173-180.
¡¡¡¡[10]LUO R, FANG L, JIN H, et al.Antiviral activity of type I and type III interferons against porcine reproductive and respiratory syndrome virus (PRRSV) [J].Antiviral Research, 2011, 91 (2) :99-101.
¡¡¡¡[11]BROCKMEIER S L, LOVING C L, NELSON E A, et al.The presence of alpha interferon at the time of infection alters the innate and adaptive immune responses to porcine reproductive and respiratory syndrome virus[J].Clinical and Vaccine Immunology Cvi, 2012, 19 (4) :508-514.
¡¡¡¡[12]DONG S, YIN Y, SHEN S, et al.Inhibitory effects of recombinant porcine interferon-alpha on high-and lowvirulence porcine reproductive and respiratory syndrome viruses[J].Research in Veterinary Science, 2012, 93 (2) :1060-1065.
¡¡¡¡[13]CHINSANGARAM J, MORAES M P, KOSTER M, et al.Novel viral disease control strategy:Adenovirus expressing alpha interferon rapidly protects swine from foot-and-mouth disease[J].Journal of Virology, 2003, 77 (2) :1621-1625.
¡¡¡¡[14]KIM S M, PARK J H, LEE K N, et al.Enhanced inhibition of foot-and-mouth disease virus by combinations of porcine interferon-alpha and antiviral agents[J].Antiviral Research, 2012, 96 (2) :213-220.
¡¡¡¡[15]MORAES M P, CHINSANGARAM J, BRUM M C, et al.Immediate protection of swine from foot-and-mouth disease:a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine[J].Vaccine, 2003, 22 (2) :268-279.
¡¡¡¡[16]CHINSANGARAM J, KOSTER M, GRUBMAN M J.Inhibition of L-deleted foot-and-mouth disease virus replication by alpha/beta interferon involves double-stranded RNA-dependent protein kinase[J].Journal of Virology, 2001, 75 (2) :5498-5503.
¡¡¡¡[17]CHENG G, ZHAO X, YAN W, et al.Alpha interferon is apowerful adjuvant for a recombinant protein vaccineagainst foot-and-mouth disease virus in swine, and an effective stimulus of in vivo immune response[J].Vaccine, 2007, 25 (28) :5199-5208.
¡¡¡¡[18]DU Y, LI Y, HE H, et al.Enhanced immunogenicity of multiple-epitopes of foot-and-mouth disease virus fused with porcine interferon alpha in mice and protective efficacy in guinea pigs and swine[J].Journal of Virological Methods, 2008, 149 (1) :144-152.
¡¡¡¡[19]DU Y, DAI J, LI Y, et al.Immune responses of recombinant adenovirus co-expressing VP1of foot-and-mouth disease virus and porcine interferon alpha in mice and guinea pigs[J].Veterinary Immunology and Immunopathology, 2008, 124 (3) :274-283.
¡¡¡¡[20]MASON P W, CHINSANGARAM J, MORAES M P, et al.Engineering better vaccines for foot-and-mouth disease[J].Developmental in Biologicals, 2003, 114:79-88.
¡¡¡¡[21]LEFEVRE F, LA BONNARDIERE C.Molecular cloning and sequencing of a gene encoding biologically active porcine alpha-interferon[J].Journal of Interferon and Cytokine Research, 1986, 6 (4) :349-360.
¡¡¡¡[22]YERLE M, GELLIN J, ECHARD G, et al.Chromosomal localization of leukocyte interferon gene in the pig (Sus scrofa domestica L) by in situ hybridization[J].Cytogenetics and Cell Genetics, 1986, 42 (3) :129-132.
¡¡¡¡[23]CHENG G, CHEN W, LI Z, et al.Characterization of the porcine alpha interferon multigene family[J].Genetics, 2006, 382 (11) :28-38.
¡¡¡¡[24]WEINGARTL H M, DERBYSHIRE J B.The induction and characterization of natural porcine interferons alpha and beta[J].Canadian Journal of Veterinary Researchrevue Canadienne de Recherche Veterinaire, 1990, 54 (3) :349-354.
¡¡¡¡[25]LEFEVRE F, L′HARIDON R, BORRAS-CUESTA F, et al.Production, purification and biological properties of an Escherichia coli-derived recombinant porcine alpha interferon[J].Journal of General Virology, 1990, 71 (5) :1057-1063.
¡¡¡¡[26]³ÂÌÎ, ¸ÉÈðáÔ, Áõ»ÝÀò, µÈ.ÖØ×éÖía¸ÉÈÅËØ»ùÒò¶¨µãÍ»±ä¼°Ôڴ󳦸˾úÖеıí´ï[J].ÉúÎ﹤³Ìѧ±¨, 2002, 18 (3) :339-342.
¡¡¡¡[27]Îⵤ.Öíα¸ÉÈÅËØ»ùÒòµÄ¿Ë¡¡¢±í´ï¼°Æ俹ÖíÎÁ²¡¶¾»îÐÔµÄÑо¿[D].±±¾©:ÖйúÅ©Òµ´óѧ, 2003.
¡¡¡¡[28]²ÜÈð±ø, ÕÅËØ·¼, ²Ì÷ºì, µÈ.Ò»ÖÖеÄÖía-¸ÉÈÅËØ»ùÒò¿Ë¡¼°ÆäÔڴ󳦸˾úÖбí´ï[J].Å©ÒµÉúÎï¼¼Êõѧ±¨, 2004, 12 (3) :278-282.
¡¡¡¡[29]²ÜÈð±ø, ÐìѧÇå, Öܱó, µÈ.Öía1-¸ÉÈÅËصĻùÒò¸ÄÔìÓë¸ßЧԭºË±í´ï[J].ÉúÎ﹤³Ìѧ±¨, 2004, 20 (2) :291-294.
¡¡¡¡[30]лº£Ñà, ¹ùÏö·å.Öía-¸ÉÈÅËصÄÔ­ºË±í´ï[J].»ªÄÏÅ©Òµ´óѧѧ±¨, 2004, 25 (4) :86-88.
¡¡¡¡[31]Áõռͨ, ´Þ±£°², ³©ÊæµÈ.Öía¸ÉÈÅËØÔ­ºË±í´ïÔØÌåµÄ¹¹½¨¼°±í´ï[J].ºÓÄÏÅ©Òµ´óѧѧ±¨, 2006, 40 (4) :398-401.
¡¡¡¡[32]Áõռͨ.Öíα¸ÉÈÅËØ»ùÒò¿Ë¡¡¢Ô­ºË±í´ï¼°¿¹²¡¶¾»îÐÔÑо¿[D].Ö£ÖÝ:ºÓÄÏÅ©Òµ´óѧ, 2005.
¡¡¡¡[33]´Þ±£°², ³ÂºìÓ¢, ÕÅËØ÷, µÈ.Öía¸ÉÈÅËØÔڴ󳦸˾úÖеıí´ï¼°¿¹²¡¶¾»îÐÔ¼ì²â[J].Î÷±±Å©ÁֿƼ¼´óѧѧ±¨ (×ÔÈ»¿Æѧ°æ) , 2008, 36 (4) :42-46.
¡¡¡¡[34]ÀîÎÄ»Ô, Áõæ·, Íõ¾ýΰ, µÈ.ÖØ×éÒ°Öía-¸ÉÈÅËØ»ùÒòµÄ¸ßЧ±í´ïºÍÏÂÓι¤ÒÕµÄÑз¢[J].ÖйúÉúÎ﹤³ÌÔÓÖ¾, 2008, 28 (6) :65-70.
¡¡¡¡[35]ÈòÈôDZ, ÕÔÑ©Àö, ÕÔÃ÷¾ü, µÈ.Öíα¸ÉÈÅËصÄÔ­ºË±í´ï¼°¿¹¸ßÖ²¡ÐÔÖí·±Ö³ÓëºôÎü×ÛºÏÕ÷²¡¶¾»îÐԲⶨ[J].ÖйúÔ¤·ÀÊÞҽѧ±¨, 2008, 30 (7) :570-574.
¡¡¡¡[36]³Âѩ÷, ѦÇ廪, ×£ÈÙ¸ñ, µÈ.Öí¢ñÐÍÓë¢òÐ͸ÉÈÅËصĿË¡¡¢±í´ï¼°¿¹²¡¶¾»îÐԱȽÏ.ÉúÎ﹤³Ìѧ±¨, 2009, 25 (6) :806-812.
¡¡¡¡[37]¸ßÃ÷, 껪.ÖØ×éÖíIFN-aÔ­ºË±í´ï¼°Æä»îÐÔ·ÖÎö[J].ÖйúÔ¤·ÀÊÞҽѧ±¨, 2009, 31 (11) :902-905.
¡¡¡¡[38]¼Ö×ÔÎÄ, ÂÀïÃñ, ·ë¾§¾§, µÈ.Öía-¸ÉÈÅËصÄÔ­ºË±í´ï¼°»îÐԲⶨ[J].ÉúÎï¼¼ÊõͨѶ, 2009, 20 (3) :370-372.
¡¡¡¡[39]ÏÄ¿¡±£, ÕÔ¿¡, ÌÀÈÊÊ÷, µÈ.Öía¸ÉÈÅËØ»ùÒòµÄ¿Ë¡¡¢Ô­ºË±í´ï¼°ÉúÎïѧ»îÐÔ¼ø¶¨[J].°²»ÕÒ½¿Æ´óѧѧ±¨, 2009, 44 (1) :53-56.
¡¡¡¡[40]ËÎÕñÍþ, ÖÜѧÕÂ, ÕÅÈʲÎ, µÈ.ÐÂÐÍÄÚº¬ëĽ鵼PHBϵͳ±í´ï´¿»¯PoIFN-aµÄÑо¿[J].ÄþÏÄ´óѧѧ±¨ (×ÔÈ»¿Æѧ°æ) , 2010, 31 (3) :264-268.
¡¡¡¡[41]Íò²©, ±«µÇ¿Ë, ÇÇËÉÁÖ, µÈ.Öía¸ÉÈÅËصıí´ï¼°ÔÚPAMϸ°ûϵÖп¹PRRSV»îÐÔ¼ì²â[J].ºÓÄÏÅ©Òµ¿Æѧ, 2010, 39 (3) :93-95, 99.
¡¡¡¡[42]ÑîÓÀʤ, ³Â´º»¨, ËÎÇÚÒ¶, µÈ.Öía1¸ÉÈÅËØ»ùÒòµÄ¿Ë¡ÓëÔ­ºË±í´ï[J].Öйúũѧͨ±¨, 2010, 26 (11) :1-6.
¡¡¡¡[43]ÕÔΰ¸ë, µ¥Í¬Áì, Ö콨¹ú, µÈ.Öía¡¢γ¸ÉÈÅËصÄÔ­ºË±í´ï¡¢´¿»¯¼°¿¹²¡¶¾»îÐÔ³õ²½Ñо¿[J].ÉϺ£½»Í¨´óѧѧ±¨ (Å©Òµ¿Æѧ°æ) , 2010, 28 (1) :64-69.
¡¡¡¡[44]ãÆÀö»Ô, ΣÑÞÎä, Áõ·É, µÈ.ÖØ×éÖía¸ÉÈÅËØÔڴ󳦸˾úÖеıí´ï¼°´¿»¯[J].ºÚÁú½­ÐóÄÁÊÞÒ½¿Æ¼¼°æ, 2011 (1) :99-100.
¡¡¡¡[45]Ö£Ãù, ±ß´«ÖÜ, ÍõÀÏÆß, µÈ.Öí¸ÉÈÅËØα¡¢βºÍγµÄÈںϱí´ï¼°»îÐÔ[J].ÖйúÅ©Òµ¿Æѧ, 2012, 45 (9) :1840-1847.
¡¡¡¡[46]»Æº£.Öía¸ÉÈÅËØ»ùÒòÔڱϳà½ÍĸÖеķÖÃÚ±í´ï[D].ÄϾ©:ÄϾ©Ê¦·¶´óѧ, 2005.
¡¡¡¡[47]¸ðÀö, ÀîÕð, ÓÚÈðáÔ, µÈ.Öía¸ÉÈÅËØ»ùÒòÔڱϳà½ÍĸÖеķÖÃÚ±í´ï[J].ÖйúÊÞҽѧ±¨, 2005, 25 (3) :289-292.
¡¡¡¡[48]Ò¦ÇåÏÀ, Ǯƽ, ²ÜÒã, µÈ.Öía-¸ÉÈÅËØÔڱϳà½ÍĸÖеķÖÃÚ±í´ï¼°ÆäÉúÎï»îÐԲⶨ[J].ÖйúÊÞҽѧ±¨, 2008, 28 (12) :1456-1460.
¡¡¡¡[49]ÕÅ´æ, Ҷΰ³É, ÍõÒ»³É, µÈ.Öía¸ÉÈÅËØÔڱϳà½ÍĸÖеĸßЧ±í´ïºÍ´¿»¯[J].Õ㽭ũҵѧ±¨, 2010, 22 (1) :6-9.
¡¡¡¡[50]ÕÅÀÙ, ÀîÅô·É, Àîΰΰ, µÈ.¹¦ÄÜÐÔÖía¸ÉÈÅËØ»ùÒòµÄ±í´ï¼°»îÐÔ¼ì²â[J].°²»ÕÅ©Òµ¿Æѧ, 2010, 38 (26) :14455-14456.
¡¡¡¡[51]Áõ½¡, ³ÂÈð°®, Áõɺɺ, µÈ.Öía¸ÉÈÅËØ»ùÒò¾­ÃÜÂë×Ó¸ÄÔìÔڱϳà½Íĸ¾úÖеĸßЧ·ÖÃÚ±í´ï[J].»ªÄÏÅ©Òµ´óѧѧ±¨, 2011, 32 (1) :93-97.
¡¡¡¡[52]ÍõÑå±ò, ËïÏòÀö, κսÓÂ, µÈ.Öí¸ÉÈÅËØαºÍγÔÚ¸Ë×´²¡¶¾Öй²±í´ï¼°¶ÔPRRSVÒÖÖÆ×÷ÓÃ[J].ÖйúÅ©Òµ¿Æѧ, 2011, 44 (9) :1931-1938.
¡¡¡¡[53]CUMMINS J M, MOCK R E, SHIVE B W, et al.Oral treatment of transmissible gastroenteritis with natural human interferon alpha:a field study[J].Veterinary Immunology and Immunopathology, 1995, 45 (3/4) :355-360.
¡¡¡¡[54]á¯Â·, ºØÁÁÁÁ, µËËÕÀí, µÈ.ÖØ×éÖíα¸ÉÈÅËØÖÎÁƸßÖ²¡ÐÔÖíÀ¶¶ú²¡µÄÑо¿[J].¶¯Îïҽѧ½øÕ¹, 2008, 29 (6) :15-19.
¡¡¡¡[55]ÐÜÖÒÁ¼, ÐìµÓƽ, ÀîÓÂ, µÈ.Öí»ùÒò¹¤³Ì¸´ºÏ¸ÉÈÅËضÔ×ÐÖí²¡¶¾ÐÔ¼²²¡·ÀÖÎЧ¹û¹Û²ì[J].ºþ±±ÐóÄÁÊÞÒ½, 2008 (12) :10-11.
¡¡¡¡[56]á¯Â·, á¯Î°½¨, Áõ¼üÇ¿, µÈ.Öíα-¸ÉÈÅËØÁÙ´²´Ù×ÐÖíÉú³¤¼°¼²²¡Ô¤·ÀÊÔÑé[J].ÖйúÐóÄÁÊÞÒ½, 2010, 37 (2) :141-143.
¡¡¡¡[57]´ÞÉнð.Öí¸ÉÈÅËØ»ùÒòÔÚÏÙ²¡¶¾µÄ±í´ï¼°Ó¦ÓÃ[J].ÑøÖí, 2011 (3) :61-64.
¡¡¡¡[58]Íõµ¤.ÖØ×éÖí!¸ÉÈÅËØ¿¹Öí·±Ö³ÓëºôÎü×ÛºÏÕ÷²¡¶¾µÄÓ¦ÓÃÑо¿[D].Ö£ÖÝ:ºÓÄÏÅ©Òµ´óѧ, 2009.
¡¡¡¡[59]²ÜÈð±ø, Öܹú¶°, ³ÂäßÑÔ.Öíα¸ÉÈÅËضÔÖíÔ²»·²¡¶¾2ÐÍÑǵ¥Î»ÒßÃçÃâÒßЧ¹ûµÄÓ°Ïì[J].ÐóÄÁÊÞҽѧ±¨, 2009, 40 (6) :867-872.

Ô­Îijö´¦£º¹ù¼Ñºê,ÏÄÒ¶,Àî´º»ª,çѵÂÄê.Öí¸ÉÈÅËئÁµÄ»ùÒò¹¤³ÌÑо¿ÓëÓ¦ÓÃ[J].ÉϺ£ÐóÄÁÊÞҽͨѶ,2018(06):10-16.
Ïà¹ØÄÚÈÝÍƼö
Ïà¹Ø±êÇ©£º
·µ»Ø£º»ùÒò¹¤³ÌÂÛÎÄ